2. Search Result
Search Result
Results for "

lipolysis

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

3

Biochemical Assay Reagents

9

Peptides

11

Natural
Products

1

Recombinant Proteins

1

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15859
    Atglistatin
    Maximum Cited Publications
    40 Publications Verification

    		 ATGL Metabolic Disease
    Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC50 of 0.7 μM in vitro.
    Atglistatin
  • HY-116771A
    CL 316243
    20+ Cited Publications

    		 Adrenergic Receptor Metabolic Disease
    CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors .CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate . CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence .
    CL 316243
  • HY-N0236
    Corylin
    5+ Cited Publications

    		 Antibiotic STAT Infection Metabolic Disease Cancer
    Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways .
    Corylin
  • HY-107737
    1,2-DLPC
    2 Publications Verification

    1,2-Dilauroyl-sn-glycero-3-phosphocholine

    		 Liposome Apoptosis TNF Receptor PPAR Metabolic Disease
    1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breakdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells .
    1,2-DLPC
  • HY-W018026
    Oxfenicine

    L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842

    		 Acyltransferase Apoptosis Cardiovascular Disease Metabolic Disease
    Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acids in the heart, protecting cardiac tissue from necrotic damage during ischemia, and also has an inhibitory effect on cardiac tissue apoptosis. In addition, Oxfenicine promotes lipolysis in a high-fat diet rat model. Oxfenicine can be used in the study of cardiovascular and metabolic diseases .
    Oxfenicine
  • HY-W016868
    3-Chloro-5-hydroxybenzoic acid
    2 Publications Verification

    		 Hydroxycarboxylic Acid Receptor (HCAR) Metabolic Disease
    3-Chloro-5-hydroxybenzoic acid is a potent, orally active and selective lactate receptor GPR81 agonist, with an EC50 of 16 μM for human GPR81. 3-Chloro-5-hydroxybenzoic acid exhibits favorable in vivo effects on lipolysis in a mouse model of obesity .
    3-Chloro-5-hydroxybenzoic acid
  • HY-107574
    TC-E 5003
    3 Publications Verification

    		 Histone Methyltransferase AP-1 NF-κB PKA Metabolic Disease Inflammation/Immunology Cancer
    TC-E 5003 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 1.5 µM against hPRMT1. TC-E 5003 modulates the lipopolysaccharide (LPS) (HY-D1056)-induced AP-1 and NF-κB signaling pathways with anti-inflammatory properties. TC-E 5003 also upregulates the expression of Ucp1 and Fgf21, activates protein kinase A signaling and lipolysis in primary subcutaneous adipocytes from both mouse and humans. TC-E 5003 is promising for research of obesity and associated metabolic disorders, oxidative stress, inflammation and cancers .
    TC-E 5003
  • HY-W015560
    3,5-Dihydroxybenzoic acid

    		Endogenous Metabolite Tyrosinase Hydroxycarboxylic Acid Receptor (HCAR) Metabolic Disease
    3,5-Dihydroxybenzoic acid a potential biomarker for the consumption of many food products, including beer, nuts, peanut, and pulses. 3,5-Dihydroxybenzoic acid is the agonist for hydroxycarboxylic acid receptor 1 (HCA1, also known as GPR81) that inhibits lipolysis in adipocytes. 3,5-Dihydroxybenzoic acid is the competitive inhibitor for tyrosine phenol-lyase (TPL), exhibits an affinity of Ki=25.7 μM. 3,5-Dihydroxybenzoic acid is orally active .
    3,5-Dihydroxybenzoic acid
  • HY-W140439
    1-Oleoyl-sn-glycero-3-phosphocholine

    18:1 Lyso PC

    		 Endogenous Metabolite Inflammation/Immunology
    1-Oleoyl-sn-glycero-3-phosphocholine (18:1 Lyso PC), a lysophospholipid, is a GPR82 inhibitor. 1-Oleoyl-sn-glycero-3-phosphocholine abrogates constitutive Gi-coupled GPR82 activity, shifts active/inactive equilibrium to inactive, suppresses Gi protein activation, increases cAMP production, and decreases GTPγS binding to Gαi proteins. 1-Oleoyl-sn-glycero-3-phosphocholine contributes to adipocyte lipolysis regulation.1-Oleoyl-sn-glycero-3-phosphocholine exhibits reduced serum levels in mouse models of steatohepatitis, linked to hepatic Lpcat 1-4 up-regulation .
    1-Oleoyl-sn-glycero-3-phosphocholine
  • HY-W013061
    Propane-1,2,3-triyl tripalmitate

    		Endogenous Metabolite Metabolic Disease
    Propane-1,2,3-triyl tripalmitate is a saturated fat. Propane-1,2,3-triyl tripalmitate enhances the lymphatic transport of Glycerol tristearate (HY-127035) .
    Propane-1,2,3-triyl tripalmitate
  • HY-B0283
    Acipimox
    2 Publications Verification

    K-9321

    		 Carbonic Anhydrase Metabolic Disease
    Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox
  • HY-135982
    GPR81 agonist 1
    4 Publications Verification

    		 Hydroxycarboxylic Acid Receptor (HCAR) Metabolic Disease
    GPR81 agonist 1 is a potent and highly selective GPR81 agonist, with EC50s of 58 nM and 50 nM for human and mouse GPR81, respectively. GPR81 agonist 1 inhibits lipolysis in differentiated 3T3-L1 adipocytes. GPR81 agonist 1 suppresses lipolysis in mice without cutaneous flushing. GPR81 agonist 1 displays remarkable selectivity for GPR81 over GPR109a .
    GPR81 agonist 1
  • HY-153523
    Hi 76-0079
    1 Publications Verification

    NNC0076-0079; 76-0079

    		 Lipase Metabolic Disease
    Hi 76-0079 (NNC0076-0079; 76-0079) is a lipase inhibitor that specifically targets hormone-sensitive lipase (HSL). Hi 76-0079 inhibits PNPB Hydrolysis in cell lysates of HEK293A cells overexpressing Lipe with an IC50 value of 0.1 μM. Hi 76-0079 synergizes with the ATGL inhibitor Atglistatin (HY-15859) to block lipolysis in vitro. Hi 76-0079 can be used for the study of lipid metabolism .
    Hi 76-0079
  • HY-107580
    GPR109 receptor agonist-1

    		GPR109A Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    GPR109 receptor agonist-1 is a highly selective agonist of the human orphan G protein-coupled receptor GPR109b, and does not activate the mouse homologous receptor PUMA-G. GPR109 receptor agonist-1 functionally modulates the human GPR109b receptor via the cAMP signaling pathway, with an EC50 of 400 nM. GPR109 receptor agonist-1 inhibits isoproterenol (HY-B0468)-stimulated lipolysis in human subcutaneous adipocytes, with efficacy comparable to that of Niacin (HY-B0143), and does not act on β-adrenergic receptors. GPR109 receptor agonist-1 can be used in studies related to dyslipidemia and atherosclerosis .
    GPR109 receptor agonist-1
  • HY-114011
    AMG7703

    		Free Fatty Acid Receptor Metabolic Disease Inflammation/Immunology
    AMG7703 is a selective and allosteric agonists of FFA2 (GPR43), the receptor for short-chain fatty acids (SCFAs), acetate, and propionate. AMG7703 can be used to research for in inflammatory and metabolic .
    AMG7703
  • HY-P5275
    Tripeptide-41

    CG-Lipoxyn

    		 NF-κB Histone Demethylase Metabolic Disease
    Tripeptide-41 (CG-Lipoxyn) is a signal peptide. Tripeptide-41 activates the NF-kB signaling pathway, inhibits the expression of C/EBP and increases cAMP. Tripeptide-41 is an important intracellular signaling factor that causes lipolysis by promoting the hydrolysis of lipids into triglycerides. Tripeptide-41 can be used in cosmetics that targets fat accumulation .
    Tripeptide-41
  • HY-101325
    (S,S)-BRL-37344 sodium

    		Drug Isomer Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    (S,S)-BRL-37344 sodium is an isomer of BRL-37344 (HY-101325B). BRL-37344 is a β-adrenoceptor agonist with EC50 values of 5.3, 18 and 570 nM for β3, β2 and β1. BRL-37344 induces concentration-dependent increases in atria1 rate, relaxation of guinea pig trachea and lipolysis of brown adipocytes .
    (S,S)-BRL-37344 sodium
  • HY-119222
    GSK256073
    2 Publications Verification

    		 GPR109A Metabolic Disease
    GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia . GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
    GSK256073
  • HY-113058
    3-Hydroxyoctanoic acid

    		Endogenous Metabolite Metabolic Disease
    3-Hydroxyoctanoic acid is a hydroxylated fatty acid that has been found in the LPS of Pseudomonas aeruginosa and in methyl-branched poly(3-hydroxyalkanoate) (PHA) polymers produced by Pseudomonas oleophores. It is an agonist of the orphan receptor GPR109B, increasing intracellular calcium in human neutrophils endogenously expressing GPR109B. 3-Hydroxycaprylic acid prevents lipolysis in human adipocytes and is upregulated in human plasma in response to a ketogenic diet. Plasma levels of 3-hydroxyoctanoic acid were also increased 3.41-fold in human male runners exhausted on a treadmill and in a mouse model of autism spectrum disorder (ASD) fed a high-glycemic diet.
    3-Hydroxyoctanoic acid
  • HY-125254
    LEI110
    1 Publications Verification

    		 Phospholipase HRASLS Infection Metabolic Disease
    LEI110 is a potent, selective and cell-permeable pan-inhibitor of the HRASLS family of thiol hydrolases. LEI110 inhibits PLA2G16, HRASLS2, RARRES3 and iNAT, with pIC50 values of 7.0, 6.8, 6.8, and 7.6, respectively. LEI110 reduces cellular arachidonic acid levels and oleic acid-induced lipolysis in HepG2 cells .
    LEI110
  • HY-120602
    WWL229

    		Carboxylesterase (CES) PPAR Interleukin Related Mitochondrial Metabolism Metabolic Disease Inflammation/Immunology
    WWL229 is a selective inhibitor of carboxylesterase 3 (CES3) with an IC50 1.94 μM. WWL229 attenuates LPS (HY-D1056)-induced pro-inflammatory cytokine mRNA levels, inhibits lipolysis and adipose thermogenesis, impairs mitochondrial function, and promotes lipid storage. WWL229 can be used for the research of obesity, insulin resistance, type 2 diabetes, and lung inflammation .
    WWL229
  • HY-111952
    SR-4995

    CID 16016685

    		 Endogenous Metabolite Others
    SR-4995 (CID 16016685) is a highly effective and selective ligand for α-β-hydrolase domain-containing 5 (ABHD5), facilitating the activation of adipose triglyceride lipase (ATGL) by displacing ABHD5 from its inhibitory regulators, perilipin-1 (PLIN1) and PLIN5. It directly interacts with ABHD5, inhibiting its association with PLIN1, and promotes lipolysis in adipocytes and muscle tissues while circumventing PKA-dependent signaling pathways.
    SR-4995
  • HY-116771
    CL 316243 free acid
    20+ Cited Publications

    		 Adrenergic Receptor Metabolic Disease
    CL316243 free acid is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors. CL316243 free acid is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 free acid has the potential for the treatment obesity, diabetes and urge urinary incontinence .
    CL 316243 free acid
  • HY-19842
    GS-9667

    CVT 3619

    		 Adenosine Receptor Cardiovascular Disease Metabolic Disease
    GS-9667 (CVT 3619), a novel N 6-5'-substituted adenosine analog, is a selective, partial agonist of the A1 adenosine receptor (A1AdoR). GS-9667 binds to adipocyte membranes with high (KH=14 nM) and low (KL=5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC50 values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA) .
    GS-9667
  • HY-N4218
    Saikosaponin B4

    		Others Metabolic Disease
    Saikosaponin B4 is a member of saikosaponins isolated from the roots of Bupleurum chinensis, selectively inhibits ACTH-induced lipolysis .
    Saikosaponin B4
  • HY-153813
    Z16078526

    		p38 MAPK Mitochondrial Metabolism Others
    Z16078526 induces endogenous Ucp1 expression, promotes p38 MAPK phosphorylation and lipolysis in primary mouse brown adipocytes. Z16078526 activates thermogenic gene expression and mitochondrial activity (uncoupled respiration) in mouse brown adipocytes. Z16078526 also stimulates thermogenesis in the mouse .
    Z16078526
  • HY-111953
    SR-4559

    		MAGL ATGL Metabolic Disease
    SR-4559 is a α/β hydrolase domain-containing protein 5 (ABHD5) ligand. SR-4559 activates adipose triglyceride lipase (ATGL) and stimulates lipolysis by inhibiting ABHD5-PLIN interactions in adipocytes and muscle cells. SR-4559 can be used for metabolic diseases like Chanarin Dorfman syndrome research .
    SR-4559
  • HY-139058
    23-epi-26-Deoxyactein

    27-Deoxyactein

    		 PPAR Metabolic Disease Cancer
    23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound .
    23-epi-26-Deoxyactein
  • HY-P3650
    Cholecystokinin (1-21)

    CCK-1-21

    		 Cholecystokinin Receptor Metabolic Disease
    Cholecystokinin (1-21) (CCK-1-21) is a cholecystokinin (CCK) fragment. Cholecystokinin (1-21) stimulates lipolysis in human adipose tissue .
    Cholecystokinin (1-21)
  • HY-15859R
    Atglistatin (Standard)

    		ATGL Metabolic Disease
    Atglistatin (Standard) is the analytical standard of Atglistatin. This product is intended for research and analytical applications. Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC50 of 0.7 μM in vitro.
    Atglistatin (Standard)
  • HY-101325A
    (S,S)-BRL-37344

    		Drug Isomer Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    (S,S)-BRL-37344 is an isomer of BRL-37344 (HY-101325B). BRL-37344 is a β-adrenoceptor agonist with EC50 values of 5.3, 18 and 570 nM for β3, β2 and β1. BRL-37344 induces concentration-dependent increases in atria1 rate, relaxation of guinea pig trachea and lipolysis of brown adipocytes .
    (S,S)-BRL-37344
  • HY-123468
    HA-1004

    		Cyclic GMP-AMP Synthase PKA ERK Tyrosine Hydroxylase Calcium Channel Cardiovascular Disease Metabolic Disease
    HA-1004 is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .
    HA-1004
  • HY-114911
    Feprazone

    DA2370; Prenazone; Zepelin

    		 COX Reactive Oxygen Species (ROS) MMP Inflammation/Immunology
    Feprazone (DA2370; Prenazone), an analogue of Phenylbutazone (HY-B0230), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities. Feprazone acts by inhibiting the activity of cyclooxygenase (COX)-2. Feprazone ameliorates free fatty acid (FFA)-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). Feprazone can decrease the expression of MMP-2 and MMP-9. Besides, Feprazone can suppress adipogenesis and increase lipolysis in differentiating 3 T3-L1 cells. Feprazone also can be used to research atherosclerosis and obesity .
    Feprazone
  • HY-W015560R
    3,5-Dihydroxybenzoic acid (Standard)

    		Reference Standards Endogenous Metabolite Tyrosinase Hydroxycarboxylic Acid Receptor (HCAR) Metabolic Disease
    3,5-Dihydroxybenzoic acid (Standard) is the analytical standard of 3,5-Dihydroxybenzoic acid. This product is intended for research and analytical applications. 3,5-Dihydroxybenzoic acid a potential biomarker for the consumption of many food products, including beer, nuts, peanut, and pulses. 3,5-Dihydroxybenzoic acid is the agonist for hydroxycarboxylic acid receptor 1 (HCA1, also known as GPR81) that inhibits lipolysis in adipocytes. 3,5-Dihydroxybenzoic acid is the competitive inhibitor for tyrosine phenol-lyase (TPL), exhibits an affinity of Ki=25.7 μM. 3,5-Dihydroxybenzoic acid is orally active .
    3,5-Dihydroxybenzoic acid (Standard)
  • HY-147501
    TRβ agonist 3

    		Thyroid Hormone Receptor Metabolic Disease
    TRβ agonist 3 (Compound 3) is a potent agonist of TRβ. TRβ agonist 3 reduces lipid accumulation in HepG2 and promote lipolysis with comparable effects. TRβ agonist 3 is a new potential TRβ-selective thyromimetics .
    TRβ agonist 3
  • HY-147500
    TRβ agonist 2

    		Thyroid Hormone Receptor Metabolic Disease
    TRβ agonist 2 (Compound 1) is a potent agonist of TRβ. TRβ agonist 2 reduces lipid accumulation in HepG2 and promote lipolysis with comparable effects. TRβ agonist 2 is a new potential TRβ-selective thyromimetics .
    TRβ agonist 2
  • HY-B0283A
    Acipimox sodium

    K-9321 sodium

    		 Carbonic Anhydrase Metabolic Disease
    Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox sodium
  • HY-N4219
    Saikosaponin B3

    		Others Neurological Disease Metabolic Disease
    Saikosaponin B3 is a saikosaponin isolated from the roots of Bupleurum falcatum L., with analgesic effect. Saikosaponin B3 inhibits ACTH-induced lipolysis in the fat cells .
    Saikosaponin B3
  • HY-P2696
    EP 80317

    		Transmembrane Glycoprotein Cardiovascular Disease
    EP 80317 is a selective CD36 ligand. EP 80317 protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 can be used for the study of cardiovascular disease .
    EP 80317
  • HY-47823
    GPCR agonist-2

    		GPR109A Metabolic Disease
    GPCR agonist-2 (Compound 5j) is a GPCR GPR109b (HM74) agonist, with a pEC50 value of 6.51. GPCR agonist-2 can be used for research of lipid disorders .
    GPCR agonist-2
  • HY-N11924
    Foenumoside B

    		AMPK PPAR Metabolic Disease
    Foenumoside B is a triterpene saponin isolated from Lysimachia foenum-graecum. Foenumoside B activates AMPK signaling, inhibits PPARγ-induced adipogenesis, and shifts lipid metabolism toward lipolysis. Foenumoside B can be used in the study of obesity and obesity-related metabolic diseases .
    Foenumoside B
  • HY-121140
    AZ1729

    		Free Fatty Acid Receptor Metabolic Disease
    AZ1729 is a potent free fatty acid 2 receptor (FFA2) activator, acting as a direct allosteric agonist and as a positive allosteric modulator. AZ1729 increases the activity of the endogenously produced short chain fatty acid propionate in Gi-mediated pathways, but not at those transduced by Gq/G11. AZ1729 induces inhibition of isoproterenol-induced lipolysis in mouse adipocytes. AZ1729 also can Induce migration of human neutrophils. AZ1729 can be used for researching the signaling pathways of the physiological roles of FFA2 .
    AZ1729
  • HY-P2712
    Chemerin-9, mouse

    Chemerin148–156, mouse

    		 Chemerin Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Chemerin-9, mouse (Chemerin148-156, mouse) is a C-terminal nonapeptide of chemerin. Chemerin-9, mouse is a ligand for ChemR23 (EC50 = 42 nM). Chemerin-9, mouse reduces basal lipolysis in primary mouse white adipocytes(IC50 = 3.3 nM). Chemerin-9, mouse enhances memory and relieves Aβ1-42-induced memory impairment in AD mice. Chemerin-9, mouse also inhibits atherogenesis .
    Chemerin-9, mouse
  • HY-112348
    HA-1004 hydrochloride

    		Cyclic GMP-AMP Synthase PKA ERK Calcium Channel Cardiovascular Disease Metabolic Disease
    HA-1004 hydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 hydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein (Cyclic GMP-AMP Synthase), and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 hydrochloride an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .
    HA-1004 hydrochloride
  • HY-114754
    BemPPOX

    		Lipase Metabolic Disease
    BemPPOX is an orally active, potent dog gastric lipase (DGL) inhibitor with Xl50 (the inhibitor molar excess leading to 50% lipase inhibition) of 0.5. BemPPOX is also a good inhibitor of GPLRP2 (xl50=0.64). BemPPOX efficiently regulates the gastrointestinal lipolysis and slows down the overall lipolysis process in rats. BemPPOX has the potential for obesity research .
    BemPPOX
  • HY-P1210
    Lys-γ3-MSH(human)

    		Melanocortin Receptor Endocrinology
    Lys-γ3-MSH(human) is a melanocortin peptide derived from the C-terminal of the fragment of pro-opiomelanocortin (POMC). Lys-γ3-MSH(human) potentiates the steroidogenic response of the rat adrenal to adrenocorticotrophin (ACTH). Lys-γ3-MSH(human) is a potent stimulator of lipolysis with an apparent EC50 of 3.56 nM. Lys-γ3-MSH(human) can activate hormone sensitive lipase (HSL) and Perilipin A resulting in lipolysis .
    Lys-γ3-MSH(human)
  • HY-P1210A
    Lys-γ3-MSH(human) TFA

    		Melanocortin Receptor Endocrinology
    Lys-γ3-MSH(human) TFA is a melanocortin peptide derived from the C-terminal of the fragment of pro-opiomelanocortin (POMC). Lys-γ3-MSH(human) TFA potentiates the steroidogenic response of the rat adrenal to adrenocorticotrophin (ACTH). Lys-γ3-MSH(human) TFA is a potent stimulator of lipolysis with an apparent EC50 of 3.56 nM. Lys-γ3-MSH(human) TFA can activate hormone sensitive lipase (HSL) and Perilipin A resulting in lipolysis .
    Lys-γ3-MSH(human) TFA
  • HY-125096
    C108297

    		Glucocorticoid Receptor Metabolic Disease Inflammation/Immunology
    C108297 is a selective glucocorticoid receptor (GR) modulator (GR binding Ki 0.7 nM; GR reporter gene functional Ki 0.6 nM). C108297 attenuates obesity by reducing caloric intake and increasing lipolysis and fat oxidation, and in addition attenuates inflammation .
    C108297
  • HY-A0231
    Glymidine sodium

    Gondafon; Glycodiazine

    		 Insulin Receptor Metabolic Disease
    Glymidine sodium is an oral active antidiabetic. Glymidine sodium is the inhibitor of hepatic lipolysis. Glymidine sodium inhibits the glucose formation and supresses the elevated pyruvate oxidation which results from the inhibition of endogenous lipid mobilization .
    Glymidine sodium
  • HY-B0283R
    Acipimox (Standard)

    K-9321 (Standard)

    		 Carbonic Anhydrase Reference Standards Metabolic Disease
    Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: